Group 1 - The company, Haixin Co., Ltd. (600851.SH), announced the intention to transfer the drug approval documents held by its subsidiary, Xi'an Haixin Pharmaceutical Co., Ltd., due to weak profitability and high asset-liability ratio [1] - The company holds a 55% stake in Xi'an Haixin and aims to maximize asset value and recover funds through this transfer [1] - Xi'an Haixin will maintain its current drug production and sales operations until the transfer target for the drug approval documents is determined [1]

Core Viewpoint - The company plans to transfer its drug approval documents held by its subsidiary, Xi'an Haixin Pharmaceutical Co., Ltd., to maximize asset value and recover funds due to weak profitability and high debt ratio [1] Group 1 - The company holds a 55% stake in Xi'an Haixin [1] - The decision to transfer drug approval documents comes after a comprehensive assessment of the subsidiary's financial health [1] - Xi'an Haixin will maintain its current drug production and sales operations until the transfer target is determined [1]